Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma

Trial Profile

Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Sep 2017

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab; Temozolomide
  • Indications Glioblastoma
  • Focus Adverse reactions
  • Most Recent Events

    • 17 Aug 2017 Planned primary completion date changed from 31 Jul 2017 to 1 Nov 2017.
    • 17 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 26 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top